Health Care & Life Sciences » Pharmaceuticals | KYORIN Holdings Inc.

KYORIN Holdings Inc. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
48,982
48,519
51,701
48,626
44,716
32,508
Total Accounts Receivable
44,123
47,007
48,296
46,192
47,819
52,590
Inventories
21,697
25,928
27,665
24,378
23,307
25,419
Other Current Assets
6,836
7,610
10,821
7,068
6,253
4,384
Total Current Assets
121,638
129,064
138,483
126,267
122,098
114,904
Net Property, Plant & Equipment
20,841
19,374
22,788
22,432
21,901
21,792
Total Investments and Advances
23,682
30,879
33,338
40,582
50,715
29,799
Long-Term Note Receivable
4
3
2
2
4
4
Intangible Assets
1,198
1,184
1,201
1,204
1,750
3,401
Other Assets
1,561
2,795
1,900
1,797
1,691
1,603
Total Assets
169,378
183,383
197,825
192,668
198,350
173,034
ST Debt & Current Portion LT Debt
1,766
1,455
1,974
1,419
1,056
Accounts Payable
11,056
11,259
11,792
11,157
10,266
Income Tax Payable
2,361
2,440
3,121
1,194
2,317
Other Current Liabilities
13,218
12,619
11,165
11,263
11,495
Total Current Liabilities
28,401
27,773
28,052
25,033
25,134
Long-Term Debt
626
2,627
4,594
4,265
4,491
Provision for Risks & Charges
2,087
378
3,100
1,676
2,140
Deferred Taxes
454
2,731
2,500
1,686
2,682
Other Liabilities
443
1,190
2,417
1,771
414
Total Liabilities
31,557
34,783
40,776
34,812
35,049
Common Equity (Total)
137,821
148,600
157,049
157,837
163,297
Total Shareholders' Equity
137,821
148,600
157,049
157,837
163,297
Total Equity
137,821
148,600
157,049
157,837
163,297
Liabilities & Shareholders' Equity
169,378
183,383
197,825
192,649
198,346

About KYORIN Holdings

View Profile
Address
Ochanomizu Sola City, 16/F
Tokyo Tokyo 101
Japan
Employees -
Website http://www.kyorin-gr.co.jp
Updated 07/08/2019
KYORIN Holdings, Inc. engages in the development, manufacture and sale of pharmaceutical products through its subsidiaries. It operates through the following segments: Pharmaceutical Business and Healthcare Business. The Pharmaceutical Business segment engages in the production and sales of prescription drugs, generic drugs, and over the counter drugs.